Zhejiang Hisoar Pharmaceutical Co., Ltd.

SZSE:002099 Stock Report

Market Cap: CN¥9.4b

Zhejiang Hisoar Pharmaceutical Past Earnings Performance

Past criteria checks 0/6

Zhejiang Hisoar Pharmaceutical's earnings have been declining at an average annual rate of -65.1%, while the Pharmaceuticals industry saw earnings growing at 9.2% annually. Revenues have been declining at an average rate of 4.8% per year.

Key information

-65.1%

Earnings growth rate

-65.6%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate-4.8%
Return on equity-7.8%
Net Margin-20.8%
Last Earnings Update31 Mar 2024

Recent past performance updates

Recent updates

Zhejiang Hisoar Pharmaceutical (SZSE:002099) Has Debt But No Earnings; Should You Worry?

May 27
Zhejiang Hisoar Pharmaceutical (SZSE:002099) Has Debt But No Earnings; Should You Worry?

Zhejiang Hisoar Pharmaceutical Co., Ltd.'s (SZSE:002099) Shares Climb 28% But Its Business Is Yet to Catch Up

Mar 03
Zhejiang Hisoar Pharmaceutical Co., Ltd.'s (SZSE:002099) Shares Climb 28% But Its Business Is Yet to Catch Up

Revenue & Expenses Breakdown

How Zhejiang Hisoar Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SZSE:002099 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 242,066-430337115
31 Dec 232,172-420332116
30 Sep 232,310-158301129
30 Jun 232,433-64342136
31 Mar 232,53443383141
01 Jan 232,70488425145
30 Sep 222,765226466149
30 Jun 222,764206518154
31 Mar 222,647125522159
01 Jan 222,48595574165
30 Sep 212,31034558166
30 Jun 212,352115527153
31 Mar 212,538272484146
31 Dec 202,471320465132
30 Sep 202,518443444123
30 Jun 202,517541409123
31 Mar 202,685673408118
31 Dec 192,941771394123
30 Sep 193,030812407122
30 Jun 193,085825408119
31 Mar 192,940763416117
31 Dec 182,719605371111
30 Sep 182,651540368118
30 Jun 182,447375304167
31 Mar 182,335271297139
31 Dec 172,309342323114
30 Sep 172,2517638877
30 Jun 172,3761654770
31 Mar 172,3762085110
31 Dec 162,4342255080
30 Sep 162,4935004690
30 Jun 162,4754894700
31 Mar 162,4864894670
31 Dec 152,4645174680
30 Sep 152,3554964640
30 Jun 152,0363783790
31 Mar 151,6692113100
31 Dec 141,319542590
30 Sep 141,158-512200
30 Jun 141,126-772240
31 Mar 141,135-822230
31 Dec 131,161-822110
30 Sep 131,060-721850
30 Jun 131,096-441830

Quality Earnings: 002099 is currently unprofitable.

Growing Profit Margin: 002099 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 002099 is unprofitable, and losses have increased over the past 5 years at a rate of 65.1% per year.

Accelerating Growth: Unable to compare 002099's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 002099 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.8%).


Return on Equity

High ROE: 002099 has a negative Return on Equity (-7.79%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.